Abbot Pakistan

Product Portfolio of Abbott Pakistan

History:
In 1888 Dr. Wallace C. Abbott, a working physician and medical store owner founded the
Abbott Alkaloidal Company. Dr. Abbott begins producing dosimetric granules in his
apartment on Chicago's North Side. The need for these granules grows away from that of his
patients and then in 1900 the business is started officially in Illinois as the Abbott Alkaloidal
Company.
When the companys overseas sales and reputation was growing, Abbott had to consider new
ways to organize its sections. Abbott had increased its business in New York, San Francisco,
Seattle and Toronto over 700 products in its register. In 1915, Abbott Alkaloid business
publicly altered its name to Abbott Laboratories.
In 1929 Abbott listed in the stock exchange of Chicago, and started its business publically.
Now Abbott is providing services in more than 120 countries and became a global
modernizer in healthcare and modern products. Abbott Butyl, a butyl alcohol-based local
anesthetic, which started Abbotts revolutionary role in the progress of anesthesia products.
In 1931 Abbott expands its business internationally and made an international office in
Montreal, Canada.
In 1962 Abbott entered into a joint venture with Dainippon Pharmaceutical Co., Ltd., of
Osaka, Japan, to manufacture radio-pharmaceuticals. Beside this, Abbotts expansion projects
in England, Italy and France were also completed. Abbott adopted an International Division
Structure with all these developments.
In 1964 Abbott acquires M&R Dietetic Laboratories of Columbus, Ohio.
In 1967, Abbott Laboratories successfully challenged the FDA on labeling regulations before
the Supreme Court in Abbott Laboratories v. Gardner.
In 1973 Abbott decided to launch the diagnostic products and services and for this purpose
Abbott forms its diagnostic division.

Abbot Pakistan

In 1997 Abbott acquires the parenteral products business of Sanofi Pharmaceuticals, Inc., and
also launches several new products, including an improved version of Similac infant formula
in the U.S.
In 2001, Abbott completes the acquisition of the pharmaceutical business of BASF, including
the global operations of Knoll Pharmaceuticals for $6.9 billion. This deal was intended to
improve Abbotts drug research business and provide it access to several experimental
medicines.
Abbott also acquires Vysis, Inc., a leading genomic disease management company.
In 2010, Abbott acquires Solvay Pharmaceuticals and STARLIMS.

Introduction:
Abbott was founded by Chicago physician, Dr. Wallace Calvin Abbott in 1888. Abbott
Laboratories is an American global pharmaceuticals and health care products company. It
has 90,000 employees and operates in over 130 countries. The company headquarters are in
Abbott Park, North Chicago, Illinois. In 2010, Abbott had over $35 billion in revenue.
Abbott is a part of global, broad-based health care company devoted to providing efficacious,
safe and cost effective medicines, new technologies and innovative ways to manage health.
Abbott is a diverse, global health care Company with scientific expertise and products that
address the full range of health care needs - from disease prevention and diagnosis to
treatment and cure.

Vision
To be a premier healthcare company in Pakistan.

Mission
To deliver consistently superior products and services which contribute significantly to
improve the quality of life of consumers.

Abbot Pakistan

Our work across broad lines of business gives us a wealth of knowledge, understanding and
capabilities in a number of health areas, including:

Pharmaceuticals
Nutritional
Diagnostics
Diabetes Care
General Health Care

Abbott's in vitro diagnostics business is a world leader in immunoassays and blood screening.
Abbott's broad range of medical tests and diagnostic instrument systems are used worldwide
by hospitals, laboratories, blood banks, and physician offices to diagnose and monitor
diseases such as HIV, hepatitis, cancer, heart failure and metabolic disorders, as well as assess
other important indicators of general health.
Abbott health care products are designed to meet important societal needs - needs that are
best met when we work collaboratively with suppliers, health care professionals and patients.
Recognizing that all health care products and procedures entail some degree of risk, we are
committed to working with a broad range of stakeholders to minimize these potential risks
while optimizing opportunities for improved health and well-being.
Our broad scientific expertise enables us to create new health care products, carry them
through the critical stages of development and then deliver them to patients and health care
providers around the world. Our diverse portfolio of pharmaceuticals, nutritionals, medical
and diagnostic devices share a common framework of excellence in science, research,
development and engineering.
Our ability to create life-enhancing and life-preserving products is constantly bolstered by
scientific advances, but delivering on our commitment to patients and consumers goes well
beyond the laboratory.
Along with educating patients and health care professionals about the safe use of our
products, we work hard to ensure safety and consumer protection throughout the
manufacturing and distribution process.

Abbot Pakistan
The safety of many product ingredients is generating significant debate throughout the health
care industry. At the same time, the broad geographic dispersion of our supply chain requires
increased oversight and auditing.
Abbott Pakistan is part of the global healthcare corporation of Abbott Laboratories, Chicago,
USA. Abbott started operations in Pakistan as a marketing affiliate in 1948; the company has
steadily expanded to comprise a work force of over 1500 employees. Currently two
manufacturing facilities located at Landhi and Korangi in Karachi continue to use innovative
technology to produce top quality pharmaceutical products.
Abbott Pakistan has leadership in the field of Pain Management, Anesthesia, Medical
Nutrition and Anti-Invectives. Our wide range of products is managed and marketed through
three marketing arms.
On June 29, 2005 Abbott Pakistan Achieved Class 'A' accreditation against the Oliver Wight
ABCD Check list. This was an outstanding achievement, which puts Abbott Pakistan
amongst some of the best global companies in terms of operational excellence.
A continuous process of innovation, research and development at Abbott's worldwide
facilities enables Abbott Pakistan to offer effective solutions for various healthcare
challenges, with products and services that are well focused, within the customer's reach and
contribute to improved health care of the people of Pakistan.
Abbott believes that Corporate Social Responsibility is fundamental to earning and deepening
the trust of the people it serves, an integral part of its commitment to improve lives has
contributed to a number of humanitarian causes and supported various institutions in various
fields including health and education.
The promise of our company is in the promise that our work holds for health and for life.

Abbot Pakistan

Executive Summary:
In 1988 Dr. Wallace C. Abbott founded Abbott Laboratories in Chicago. Over the last decades
Abbott has grown up into a diversified medical products company. It is developing,
producing and marketing a high portfolio of products that are used in prevention, treatment,
diagnosis and care. It has basically two product group lines:

The Pharmaceutical Product Group

The Medical Device Product Group

The organization has 90,000 employees working worldwide in 130 countries. Worldwide
Pharmaceutical sales accounted for 59% of revenues in 2004, worldwide Nutritional sales for
20%, worldwide Diagnostics for 17%, and worldwide Other/Non Segment for 4%.
Abbott Laboratories belongs to the brand pharmaceutical industry, a highly competitive
industry and they rely on R&D to make new innovations in drugs.
By securing patents for these discoveries, other brand pharmaceutical companies are able to
protect their drugs against duplicate. In this industry patent protection lasts for 20 years, but
the long development process necessary to bring drugs to market makes their effective
lifespan a little over a decade.
However, the relatively inelastic demand curve of consumers who purchase prescription
drugs through pharmacies allow Abbott to extract high profit margins. Substitutes for
Abbotts drugs include drugs from other brand pharmaceutical companies with similar
benefits and generic versions of Abbotts drugs whose patents have expired.
Although research-based pharmaceuticals have been Abbotts main line of business
throughout the past century, in recent years they have shifted more of their focus on to the
diversified medical product sector. 2011 when they announced the spinning off of their
research-based pharmaceutical business and the intention to keep the diversified medical
products under the Abbott name.

Abbot Pakistan

Research and development costs for new drugs remain high in recent years and increased
government regulation projected to shorten patent protection periods has made it increasingly
difficult for pharmaceutical companies to produce high enough revenues to cover their costs
of production.
Griffin agrees with Abbotts decision to shift their focus away from branded pharmaceuticals
towards other pillars of their business. They will, however, need to focus on increasing their
margins in these lines of business, especially as they expand internationally in to high-growth
emerging markets.
In 2011 Abbott has already begun expanding overseas. Abbott is one of few companies
diversified and developed enough to produce such a product, and as such has seen the stent
become a best-selling product with essentially no viable competitors.
While they still operate both lines of business it is in Abbotts best interest to develop
synergies between their product lines. Currently, although it is a diversified company, Abbott
operates its product lines fairly independently.
By creating more synergies within the branches of its business Abbott can take advantage of
economies of scope and create novel products that carve out their own distinct niches in the
marketplace.
Abbott can pursue is further diversifying their product line through acquisitions of biotech
companies. Biotech products tend to be produced using microorganisms and DNA, making
them much more difficult to copy than traditional pharmaceutical compounds.
This complexity will allow Abbott to retain more market share of their products after the
patent expires, reducing their exposure to generic erosion, the main threat for all big
pharmaceutical companies.